N/A
N=52
Yoga, Immune Function, and Health
Healthy
Bottom Line
View on ClinicalTrials.gov: NCT00371397 ↗Enrolled (actual)
52
Serious AEs
0.0%
Results posted
Jul 2011
Primary outcome: Primary: Number of Participants With Detectable C-Reactive Protein (CRP) — 16; 8 participants with CRP above 0.3 — p=.009
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Hatha Yoga Classes (Behavioral); Movement Control (Behavioral)
- Age
- Adult, Older Adult · 30+ yrs
- Sex
- Female
- Sponsor
- Ohio State University
- Primary completion
- Sep 2008
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Detectable C-Reactive Protein (CRP) |
16; 8 | .009 sig |
| PRIMARY Cortisol |
— | — |
| PRIMARY Skin Barrier Repair: Trans-epidermal Water Loss (TEWL) |
— | — |
| PRIMARY Immune Function: Soluble Interleukin-6 Receptor (sIL-6r) |
— | — |
| PRIMARY Immune Function: Tumor Necrosis Factor-alpha (TNF-α) |
— | — |
| PRIMARY Immune Function: Lipopolysaccharide (LPS) -Stimulated Production of Interleukin-6 (IL-6) |
— | — |
| PRIMARY Immune Function: LPS-stimulated Production of TNF-α |
— | — |
| PRIMARY Immune Function: Interleukin-6 (IL-6) |
— | — |
| PRIMARY Catecholamine Production: Epinephrine |
— | — |
| PRIMARY Catecholamine Production: Norepinephrine |
— | — |
| SECONDARY Heart Rate |
— | — |
| SECONDARY Blood Pressure |
— | — |
| SECONDARY Mood: Positive and Negative Affect Schedule (PANAS)Positive |
— | — |
| SECONDARY Mood: Positive and Negative Affect Schedule (PANAS)Negative |
— | — |
Summary
This study is designed to examine the impact of hatha yoga on immune and hormonal functioning in healthy individuals.
Eligibility Criteria
Inclusion Criteria
- healthy female adults
- relatively inexperienced with yoga (beginner)
- experienced with yoga (advanced practitioner)
Exclusion Criteria
- Treatment with medication that has immunological or endocrinological consequences
- Chronic health problems that affect immune or endocrine systems
- Anemia
- Use of psychoactive drugs or mood-altering medication
- Smoking
- Needle or blood phobias
- Tape or bandage allergies
- Pregnancy or nursing within the previous 3 months
- Heart problems
- History of hip or knee replacement surgery, displaced vertebrae, and any other physical limitations that would prevent full participation in the program
- use of statins, beta blockers
- excessive alcohol use
- convulsive disorders
- Body Mass Index (BMI) ≥ 30.
Data sourced from ClinicalTrials.gov (NCT00371397). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.